New drug targets Hard-to-Treat cancers with KRAS mutation

NCT ID NCT04699188

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not responded to standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm lung cancer lung carcinoma lung neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF LUNG CANCER OF THE LUNG CARCINOMA, COLORECTAL CARCINOMA, NON-SMALL-CELL LUNG KRAS G12C MUTANT SOLID TUMORS LUNG CANCER NEOPLASMS, LUNG NEOPLASMS, PULMONARY PULMONARY CANCER PULMONARY NEOPLASMS

Contacts and locations

Locations

Emory University School of Medicine-Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Montreal, Quebec, H2W 1T8, Canada
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Copenhagen, DK-2100, Denmark
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Brescia, BS, 25123, Italy
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Nagoya, Aichi-ken, 4668560, Japan
Novartis Investigative Site

Kashiwa, Chiba, 2778577, Japan
Novartis Investigative Site

Osaka, Osaka, 5418567, Japan
Novartis Investigative Site

Chuo Ku, Tokyo, 1040045, Japan
Novartis Investigative Site

Koto Ku, Tokyo, 1358550, Japan
Novartis Investigative Site

Amsterdam, 1066 CX, Netherlands
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28050, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Taipei, 10002, Taiwan
Uni Of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.